$29.87+1.77 (+6.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
UroGen Pharma (URGN) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Sep 30, 2026*: more funds added or entered than trimmed or exited, mild accumulation (13 new · 28 increased · 10 reduced · 0 closed · 16 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 67 filers, Sep 30, 2026
# 13F FUNDS
67
13F VALUE
$163.2M
4.0M shares
Not reported in the company's filings for this period.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Degnan Chris | Chief Financial Officer | Acquired · Option exercise | 4,483 | — | ↗ |
| Oct 8, 2026 | Degnan Chris | Chief Financial Officer | Disposed · Open-market sale | 2,202 | $36.69 | ↗ |
| Oct 8, 2026 | Degnan Chris | Chief Financial Officer | Disposed · Option exercise | 4,483Restricted Stock Units | — | ↗ |
| Sep 8, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 871 | $42.92 | ↗ |
| Sep 8, 2026 | Smith Jason Drew | General Counsel | Disposed · Open-market sale | 1,519 | $42.54 | ↗ |
| Sep 7, 2026 | Schoenberg Mark | Chief Medical Officer | Acquired · Option exercise | 1,667 | — | ↗ |
| Sep 7, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Option exercise | 1,667Restricted Stock Units | — | ↗ |
| Sep 7, 2026 | Smith Jason Drew | General Counsel | Acquired · Option exercise | 3,334 | — | ↗ |
| Sep 7, 2026 | Smith Jason Drew | General Counsel | Disposed · Option exercise | 3,334Restricted Stock Units | — | ↗ |
| Aug 26, 2026 | Robinson James A. Jr. | director | Acquired · Option exercise | 2,000 | — | ↗ |
| Aug 26, 2026 | Robinson James A. Jr. | director | Disposed · Option exercise | 2,000Restricted Stock Unit | — | ↗ |
| Aug 20, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 60,677 | $47.05 | ↗ |
| Jul 9, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 10,000 | $40.00 | ↗ |
| Jun 22, 2026 | Schoenberg Mark | Chief Medical Officer | Disposed · Open-market sale | 10,000 | $35.01 | ↗ |
| Jun 22, 2026 | Wildman Daniel George | director | Acquired · Grant / award | 10,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | Wildman Daniel George | director | Acquired · Grant / award | 8,000Restricted Stock Unit | — | ↗ |
| Jun 22, 2026 | Robinson James A. Jr. | director | Acquired · Grant / award | 10,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | Robinson James A. Jr. | director | Acquired · Grant / award | 8,000Restricted Stock Unit | — | ↗ |
| Jun 22, 2026 | Holden Stuart | director | Acquired · Grant / award | 20,000Stock Option (right ot buy) | — | ↗ |
| Jun 22, 2026 | BUTITTA CYNTHIA M | director | Acquired · Grant / award | 10,000Stock Option (right ot buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold UroGen Pharma?
UroGen Pharma was held by 67 13F filers as of Sep 30, 2026.
Not investment advice.

